Robert Ruffolo - Jul 1, 2021 Form 4 Insider Report for Sigilon Therapeutics, Inc. (SGTX)

Role
Director
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Stock symbol
SGTX
Transactions as of
Jul 1, 2021
Transactions value $
-$66,083
Form type
4
Date filed
7/2/2021, 04:16 PM
Previous filing
Jun 28, 2021
Next filing
Oct 5, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGTX Common Stock Options Exercise $3.85K +6.75K $0.57 6.75K Jul 1, 2021 Direct F1
transaction SGTX Common Stock Sale -$69.9K -6.75K -100% $10.36* 0 Jul 1, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Options Exercise $0 -6.75K -12.15% $0.00 48.8K Jul 1, 2021 Common Stock 6.75K $0.57 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.17 to $10.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The option vested as to 25% of the underlying shares of common stock on July 14, 2017, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.